AI-generated · cited to primary sources · not investment advice
Shilpa Medicare (530549) May 2026 Filing Analysis
Does management do what it says?
Total capex for FY26 was INR 361 crores. Given that H1 FY26 capex was previously guided, the full-year figure indicates robust investment in API, CDMO, and albumin facilities. (1 exceeded across 1 tracked commitment)
“Two NBE programs will be entering in the Phase I studies in FY27.”
The API segment delivered 11% YoY growth for 3QFY26 and 17% YoY growth for 9MFY26, meeting the double-digit growth target. (3 met across 3 tracked commitments)
“We have added a new oncology block to our existing set up, increasing overall oncology API capacity. The block is expected to get commissioned in FY27.”
The company plans to launch Rotigotine Transdermal Patch in Europe in FY27. (+2 more commitments)
“Rotigotine Transdermal Patch Europe launch, as explained in the previous call, will be launched in Europe in FY27.”
See the full cited Management analysis of Shilpa Medicare
How durable is the business?
Formulation revenue reached INR 98 crores, with growth driven by European and Rest of World (ROW) markets. The company achieved a milestone with the approval of its first New Chemical Entity (NCE), Nor-Ursodeoxycholic acid. (5 expanding across 1 engine)
“Formulation revenue for the quarter were INR205 crores, growing at 54% year-on-year”
The company is strengthening its technological moat by advancing its Biologics and ADC (Antibody-Drug Conjugate) platforms, with its first ADC biosimilar expected to enter human studies in FY27. (2 expanding)
“And for the full year '26, we have had historic revenue number, delivering INR1,549 crores, growing at 18%... yearly EBITDA margin of 29%”
The API segment achieved its highest-ever Q1 performance, driven by portfolio rationalization and increased offtake from expanded capacities in products like Tranexamic acid and Ursodeoxycholic acid. (5 expanding across 1 engine)
“Our API business clocked a revenue of INR259 crores for the quarter... growing at 16%, both on a quarterly as well as yearly basis.”
Europe has emerged as a high-growth geography, with revenue more than doubling in the latest quarter due to market share gains in key products. (3 expanding)
“European formulation business, which delivered revenues of over INR200 crores, growing by more than 100% year-on-year.”
The regulatory risk remains stable as the company continues to use third-party CMOs for critical U.S. launches to bypass the Jadcherla facility's import alert status. (3 stable)
“It's just that the facility when the audit happened, the FDA has given some observations. We have done the compliance. And now we are again waiting for the reaudit of that.”
See the full cited Business Model analysis of Shilpa Medicare
Where does growth come from?
The company has resolved previous validation issues and is now scaling up 10 new blockbuster oncology products, with 3 validated this quarter and more planned for Q4 FY26. (1 accelerating across 1 signal, 1 leading indicator)
“We have added a new oncology block to our existing set up, increasing overall oncology API capacity. The block is expected to get commissioned in FY27... we have added more than 15 new oncology products to our pipeline, these are top oncology blockbusters at global level, having patent expiry up to 2032.”
The company received a major regulatory boost with the US FDA EIR for its transdermal patch facility. Rotigotine is expected to receive European approval in 2HFY26 and a US filing is planned for Q3 FY26. (3 accelerating, 2 new trend across 5 signals, 2 leading indicators)
“The main strength, what we are building in the ADC space is we are building our own ADC manufacturing suite, which will have manufacturing of mAb, manufacturing of payload, linker and conjugation. With that integrated manufacturing capability, it will be one of its kind in India.”
The biologics segment is in a high-growth phase, doubling revenue in FY26. Growth is currently driven by CDMO deals, with biosimilar licensing expected to contribute in FY27. (1 accelerating across 1 signal)
“Moving to the Biologics segment. The revenue for the year were INR150 crores, growing roughly 100% year-on-year. And the strong growth was driven by continued deal momentum that we are witnessing in our CDMO business.”
The European formulation business is accelerating, doubling its revenue year-over-year. New launches like Rotigotine and Tadalafil are expected to sustain this momentum in FY27. (1 accelerating across 1 signal, 1 leading indicator)
“Rotigotine Transdermal Patch Europe launch... will be launched in Europe in FY27... we have Tadalafil oral disintegrating film that will be launched in Europe in this financial year.”
Shilpa is developing a generic version of Semaglutide (a popular weight-loss and diabetes drug) using both synthetic and semi-synthetic methods, focusing on export markets.
“For Semaglutide, our main strength is that we are doing both synthetic and semisynthetic API. And, we are forward integrating with our own formulation... our main focus will be on the export market.”
See the full cited Future Growth analysis of Shilpa Medicare
What could break the thesis?
Management reports that Nilotinib is currently 'doing reasonably good' with a strong order book, but the long-term risk of generic entry in FY28 remains a structural concern that hasn't changed. (2 stable, 1 intensifying, 1 high-severity)
“we are expecting some generic competition to come in current financial year... The more impact will be there for the FY28. So to answer you, that is what is the answer for Nilotinib.”
The risk is easing as the company received an Establishment Inspection Report (EIR) from the U.S. FDA for its transdermal patch manufacturing facility, which is a critical step toward opening U.S. market opportunities. (4 easing, 1 stable, 1 high-severity)
“It's just that the facility when the audit happened, the FDA has given some observations. We have done the compliance. And now we are again waiting for the reaudit of that... our major focus on U.S. will be from third-party CMOs.”
The risk is INTENSIFYING as management explicitly noted that prices for raw materials and solvents have 'gone up significantly,' even though availability is stable. (1 intensifying, 1 emerging, 3 easing)
“On the debt front, our net debt for the year increased to INR 613 crores from INR 550 crores in the previous year”
The risk is INTENSIFYING as the IMPD submission has been delayed from Q4 to the first half of FY27 to accommodate testing from a new facility. (1 intensifying, 1 easing, 3 stable)
“for Aflibercept, currently, there is no plan of going into Europe market because it's a very long study and very costly study, and we feel that we are late for Europe market.”
See the full cited Risk analysis of Shilpa Medicare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.